tiprankstipranks
Trending News
More News >
Relmada Therapeutics (RLMD)
NASDAQ:RLMD
US Market

Relmada Therapeutics (RLMD) Income Statement

Compare
430 Followers

Relmada Therapeutics Income Statement

Last quarter (Q4 2025), Relmada Therapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q4, Relmada Therapeutics's net income was $-19.87M. See Relmada Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Operating Expenses
$ 1.06M$ 83.89M$ 103.70M$ 161.25M$ 125.70M
Depreciation and Amortization
$ 0.00$ 0.00$ 103.70M$ 2.00K$ 1.26K
EBITDA
$ -59.10M$ -83.89M$ 4.91M$ -161.25M$ -125.70M
Operating Income
$ -59.10M$ -83.89M$ -103.70M$ -161.25M$ -125.70M
Other Income/Expenses
$ 1.72M$ 3.91M$ 4.91M$ 4.21M$ -48.32K
Pretax Income
$ -57.39M$ -79.98M$ -98.79M$ -157.04M$ -125.75M
Net Income
$ -57.39M$ -79.98M$ -98.79M$ -157.04M$ -125.75M
Per Share Metrics
Basic EPS
$ -1.45$ -2.65$ -3.28$ -5.30$ -7.16
Diluted EPS
$ -1.45$ -2.65$ -3.28$ -5.30$ -7.16
Weighted Average Shares Outstanding
39.48M 30.16M 30.10M 29.63M 17.55M
Weighted Average Shares Outstanding (Diluted)
39.48M 30.16M 30.10M 29.63M 17.55M
Currency in USD

Relmada Therapeutics Earnings and Revenue History